---
layout: minimal-medicine
title: Lenograstim
---

# Lenograstim
### Generic Name
Lenograstim

### Usage

Lenograstim, a granulocyte colony-stimulating factor (G-CSF), is primarily used to treat neutropenia (low neutrophil count, a type of white blood cell crucial for fighting infection).  Its applications span various conditions causing this deficiency:

* **Aplastic anemia-induced neutropenia:** Lenograstim helps boost neutrophil production in patients with aplastic anemia, a condition where the bone marrow doesn't produce enough blood cells.

* **Neutropenia following bone marrow transplantation:**  After a bone marrow transplant, the body's ability to produce neutrophils is temporarily suppressed. Lenograstim helps shorten the duration of this neutropenia and reduce associated complications, like infection.

* **Chemotherapy-induced neutropenia:** Chemotherapy, while effective against cancer, often damages bone marrow, leading to neutropenia. Lenograstim is used to mitigate this side effect, reducing the risk of infections during and after cancer treatment.  This applies to patients with various cancers, including solid tumors and acute myeloid leukemia (AML) – but only in specific AML cases as described in the precautions section.


* **Chronic neutropenia (congenital or idiopathic):**  Lenograstim offers long-term management for individuals with persistently low neutrophil counts due to congenital (present from birth) or idiopathic (unknown cause) reasons.

* **Neutropenia related to HIV infection, immunosuppressive therapies (e.g., post-kidney transplant), or myelodysplastic syndromes:**  Lenograstim can help manage neutropenia in these contexts as well.

* **Hematopoietic progenitor cell mobilization:** Lenograstim increases the number of hematopoietic progenitor cells (cells that give rise to blood cells) in the peripheral blood, facilitating their collection through apheresis for transplantation purposes in both healthy donors and patients.  It can also be used to accelerate engraftment (the successful establishment of transplanted cells) after reinfusion.


### Dosage

Lenograstim dosages vary significantly depending on the specific condition, the patient's weight and body surface area (BSA), and the route of administration (subcutaneous [SubQ] injection or intravenous [IV] infusion).  The following information provides a general overview; precise dosing should always be determined by a healthcare professional based on the individual's needs.

**Note:** Lenograstim dosages are often expressed in both micrograms (mcg) and International Units (IU).


**Adults:** Dosages range from 2 mcg/kg/day to 150 mcg/m²/day depending on the indication.  Specific dosages for each condition are outlined in the product information provided.


**Children:** Dosage adjustments for children are primarily based on weight (mcg/kg/day) or BSA (mcg/m²/day) and depend on the specific indication.  Information regarding age restrictions and specific dosages for each indication in children are provided in the product information.

**Administration:**  IV infusions are typically administered over at least 30 minutes, while subcutaneous injections should use a volume no larger than 1 mL at any given injection site to minimize local reactions.

### Side Effects

**Common Side Effects (≥10%):**

* Abdominal pain
* Thrombocytopenia (low platelet count)
* Leukocytosis (high white blood cell count)
* Asthenia (weakness, fatigue)
* Musculoskeletal pain


**Less Common, but Potentially Serious Side Effects (1-10% or less frequently reported):**

* Headache
* Increased levels of liver enzymes (ALT, AST, ALP)
* Splenomegaly (enlarged spleen)
* Injection site reactions
* Fever
* Allergic reactions (ranging from mild to severe, including anaphylaxis)
* Capillary leak syndrome
* Aortitis (inflammation of the aorta)
* Pulmonary complications (pneumonia, edema, fibrosis)
* Bone pain and osteopenia (decreased bone density)
* Glomerulonephritis (kidney inflammation)
*  Malignant neoplasm (increased risk of certain cancers)


**Important Note:** This list is not exhaustive.  If you experience any unusual or concerning side effects, contact your doctor immediately.

### How it Works

Lenograstim is a recombinant human G-CSF. It works by binding to receptors on the surface of bone marrow cells that are responsible for the production and maturation of neutrophils. This binding stimulates the growth and release of neutrophils into the bloodstream, thereby increasing the neutrophil count and enhancing the body's ability to combat infections.

### Precautions

* **Contraindications:** Lenograstim is contraindicated in patients with hypersensitivity to Lenograstim or other G-CSFs (e.g., filgrastim), those with uncontrolled myeloid malignancies (except in certain AML cases as specified by the prescribing information), and those with a history of severe allergic reactions to G-CSFs.  Concomitant use with certain chemotherapeutic agents should be avoided, or used with caution under strict supervision.

* **Drug Interactions:** Lenograstim's use with myelosuppressive antineoplastic agents (cancer drugs that suppress bone marrow activity) increases the risk of myelosuppression. Concomitant use with bleomycin or cyclophosphamide may enhance pulmonary toxicity.

* **Specific Populations:**  Pregnant or breastfeeding women should discuss the risks and benefits of Lenograstim with their healthcare providers.  Use in children requires careful dose adjustment and monitoring.  Patients with sickle cell disease are at increased risk of sickle cell crisis.  The safety and efficacy in patients with severe renal or hepatic impairment haven't been specifically established.

* **Warnings:**  Lenograstim can cause serious adverse events, such as allergic reactions (including anaphylaxis), capillary leak syndrome, aortitis, and splenic rupture. Close monitoring is essential.


### FAQs

* **Q: How long does it take for Lenograstim to work?** A: The onset of effect varies depending on the indication and individual response.  Neutrophil counts typically increase within a few days.

* **Q: How should Lenograstim be stored?** A: Refer to the specific storage instructions provided on the product packaging.  Generally, it requires refrigeration.

* **Q: Can I stop taking Lenograstim abruptly?** A:  No, never stop taking Lenograstim without consulting your doctor.  Stopping abruptly may lead to a rapid decrease in neutrophil counts, increasing infection risk.  The duration of treatment is determined by your doctor.

* **Q: What should I do if I miss a dose?** A: Contact your doctor to determine the appropriate course of action.  Do not double the dose to make up for a missed dose.

* **Q: Are there any long-term effects of Lenograstim?** A:  While generally well-tolerated, prolonged use may be associated with a slightly increased risk of certain cancers; your doctor will weigh the potential risks against benefits.

**Disclaimer:**  This information is for educational purposes only and should not be considered medical advice.  Always consult with a healthcare professional before starting or changing any medication, including Lenograstim.  The product information provided should always be consulted for comprehensive and up-to-date details regarding dosage, precautions, contraindications, and other important information.
